3-羟基己酸 | 10191-24-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: 3-羟基己酸
• 英文名称: 3-hydroxyhexanoic acid
• 英文别名: 3(R,S)-hydroxyhexanoic acid；Acide hydroxy-3 hexanoique；3-Hydroxyhexanoate；n-butanolacetic acid；3-hydroxy-hexanoic acid；3-Hydroxy-capronsaeure
• CAS: 10191-24-9
• 化学式: C₆H₁₂O₃
• mdl: MFCD02259045
• 分子量: 132.159
• InChiKey: HPMGFDVTYHWBAG-UHFFFAOYSA-N

物化性质

• 熔点：
  13 °C
• 沸点：
  259.6±23.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）
• LogP：
  -0.080 (est)
• 稳定性/保质期：
  存在于烟叶中。

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥，密封。

反应信息

• 作为反应物：
  描述：

  3-羟基己酸 在 二甲基二环氧乙烷 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 3-hydroxy-5-propyl-5H-furan-2-one
  参考文献：
  名称：

  Synthesis of α-Keto Esters and Amides via Oxidative Cleavage of Cyanoketophosphoranes by Dimethyldioxirane

  摘要：

  DOI：

  10.1021/jo0015974
• 作为产物：
  描述：

  反式-2-己烯酸 在 sodium hydroxide 作用下， 生成 3-羟基己酸
  参考文献：
  名称：

  Fittig; Baker, Justus Liebigs Annalen der Chemie, 1894, vol. 283, p. 117

  摘要：

  DOI：

文献信息

• General synthetic routes to β-hydroxy-acids from t-butyl esters and the Reformatskii reaction
  作者：D. A. Cornforth、A. E. Opara、G. Read

  DOI：10.1039/j39690002799

  日期：——

  modified Reformatskii procedure which leads directly to the hydroxy-acid. With highly hindered ketones or under conditions of inverse addition, self-condensation of the Reformatskii reagents from the t-butyl esters of α-bromopropionic acid and α-bromoisobutyric acid seriously reduce the yields of β-hydroxy-esters.

  通过（a）通过Reformatskii反应制得的叔丁基β-羟基酯的脱烷基化，以及（b）直接导致羟基的改进的Reformatskii方法，可以高收率合成各种各样的β-羟基酸。-酸。在高度受阻的酮中或在反加条件下，Reformatskii试剂从α-溴丙酸和α-溴异丁酸的叔丁基酯中的自缩合会严重降低β-羟基酯的收率。
• [EN] IONIC LIQUID SOLVENTS<br/>[FR] SOLVANTS LIQUIDES IONIQUES
  申请人：UNIV DUBLIN CITY

  公开号：WO2010097412A1

  公开（公告）日：2010-09-02

  A chiral ionic compound comprising an alkyl substituted imidazolium or pyridinium cationic core having an alkyl ester side chain (-alkyl-C(O)O-) directly linked to the core and an associated counter anion, characterized in that the -O- atom of the ester side chain is linked to an alpha, a beta or a gamma hydroxycarboxylic acid functionality via the alpha, beta or gamma hydroxy of the acid functionality and the hydroxycarboxylic acid functionality has at least one asymmetric carbon, or characterized in that an -N= atom of the alkyl substituted imidazolium or pyridinium cationic core is substituted with an alpha, a beta or a gamma hydroxy group of a alpha, a beta or a gamma hydroxycarboxylic acid functionality and the hydroxycarboxylic acid functionality has at least one asymmetric carbon. The chiral ionic liquids (CILs) may be used as novel solvents, in particular for organic synthesis. The CILs have the potential to induce asymmetry into substrates or catalysts in a variety of organic transformations. A number of the compounds have low antimicrobial and low antifungal toxicities and are also biodegradable CILs.

  一种手性离子化合物，包括具有烷基取代的咪唑或吡啶阳离子核心，其具有直接连接到核心的烷基酯侧链（-烷基-C（O）O-）和相关的对应阴离子，其特征在于酯侧链的-O-原子通过α、β或γ羟基羧酸功能与羧酸功能的α、β或γ羟基相连，且羟基羧酸功能具有至少一个不对称碳，或者其特征在于烷基取代的咪唑或吡啶阳离子核心的-N=原子被α、β或γ羟基羧酸功能的α、β或γ羟基取代，且羟基羧酸功能具有至少一个不对称碳。这种手性离子液体（CILs）可用作新型溶剂，特别适用于有机合成。这些CILs有潜力在各种有机转化中向底物或催化剂引入不对称性。其中一些化合物具有低抗菌和低抗真菌毒性，并且也是可生物降解的CILs。
• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Characterization of FabG and FabI of the<i>Streptomyces coelicolor</i>Dissociated Fatty Acid Synthase
  作者：Renu Singh、Kevin A. Reynolds

  DOI：10.1002/cbic.201402670

  日期：2015.3.2

  Functional crosstalk: β‐Ketoacyl‐acyl carrier protein (ACP; FabG) and enoyl‐ACP reductase (FabI) from Streptomyces coelicolor were identified and characterized. Kinetic analysis demonstrated that these enzymes process straight and branched‐chain substrates along with the ACPs from both fatty acid and undecylprodiginine biosynthetic pathways. This relaxed substrate specificity allow these enzymes to

  功能性串扰：鉴定并鉴定了来自天蓝色链霉菌的β-酮酰基-酰基载体蛋白（ACP; FabG）和烯酰-ACP还原酶（FabI）。动力学分析表明，这些酶可处理直链和支链底物，以及来自脂肪酸和十一烷基脯氨酸的生物合成途径中的ACP。这种松弛的底物特异性使这些酶参与了两个过程。

表征谱图